Ocugen, Inc. (NASDAQ:OCGN) Q1 2021 Earnings Conference Call May 7, 2021 9:00 AM ET Company Participants Lisa DeScenza – Vice President-Integrated Communications-LaVoie Health Science Shankar Musunuri – Chairman, Chief Executive Officer and Co-Founder Sanjay Subramanian – Chief Financial Officer and Head-Corporate Development Conference Call Participants Keay Nakae – Chardan Zegbeh Jallah – ROTH Capital Robert LeBoyer – Noble Capital Swayampakula Ramakanth – H.C. Wainwright Kristen Kluska – Cantor Fitzgerald ...

Ocugen, Inc. (NASDAQ:OCGN) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Lisa DeScenza – Vice President of Integrated Communications, LaVoie Health Science Shankar Musunuri – Chairman and Chief Executive Officer Sanjay Subramanian – Chief Financial Officer and Head of Corporate Development Conference Call Participants Keay Nakae – Chardan Zegbeh Jallah – ROTH Capital Partners Swayampakula Ramakanth – H.C. Wainwright Operator Good morning, and welcome to the Ocugen Conferenc ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, prod ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to fight COVID-19 NASDAQ: OCGN Corporate Deck: January 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product appr ...

Ocugen, Inc. (NASDAQ:OCGN) Q2 2020 Results Conference Call August 14, 2020 8:30 AM ET Company Participants Lisa DeScenza - VP of Integrated Communications, LaVoie Health Science Shankar Musunuri - Chairman and CEO Sanjay Subramanian - CFO Mohamed Genead - Acting CMO and Chair of Scientific Advisory Board Conference Call Participants Keay Nakae - Chardan Ramakanth Swayampakula - H.C. Wainwright Kristen Kluska - Cantor Fitzgerald Operator Good morning and welcome to the Ocugen Conference Call. [Operator Instr ...

Ocugen, Inc. (NASDAQ:OCGN) Q4 2019 Earnings Conference Call March 27, 2020 8:30 AM ET Â Company Participants Kelly Beck - Vice President, Investor Relations and Administration Shankar Musunuri - Chairman and Chief Executive Officer Sanjay Subramanian - Chief Financial Officer Dan Jorgensen - Chief Medical Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Keay Nakae - Chardan Operator Good morning and welcome to the Ocugen Conference Call. At this time, all participants are in a l ...

Developing Transformative Therapies to Treat the Whole Eye NASDAQ: OCGN Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product approvals, research and development costs, timing and likelihood of ...

Ocugen, Inc. (NASDAQ:OCGN) Q3 2019 Results Conference Call November 8, 2019 10:30 AM ET Company Participants Kelly Beck - Vice President, Investor Relations, Administration Shankar Musunuri - Chairman and Chief Executive Officer Sanjay Subramanian - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to Ocugen Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session for research analys ...